Overview of Urofos

Property	Description
Active ingredient	Norfloxacin
Form	Film-coated tablet
Pharmacological class	Fluoroquinolone antibiotic
Common use	Elimination of bacterial infections
Origin	Synthetic compound

What Type of Medicine is Urofos?

Urofos is a prescription-only medication containing the active component Norfloxacin, which is classified as a synthetic antibacterial agent. Norfloxacin belongs specifically to the fluoroquinolone antibiotic class. This classification means Urofos is a targeted anti-infective therapy utilized to eliminate infection-causing microbes. The compound is manufactured through chemical synthesis, distinguishing its origin from antibiotics naturally derived from living organisms; its unique structure and efficacy are established features of the compound.

Composition and Form: The Norfloxacin Tablet

The medication is an oral preparation presented as a film-coated tablet designed for systemic absorption following ingestion. Urofos is a single-ingredient product, containing only Norfloxacin as the active pharmaceutical ingredient. The formulation ensures that the precise amount of the active agent is delivered reliably. Norfloxacin is primarily used to treat infections and works by stopping the growth of bacteria. This core function is to combat the presence of harmful bacteria in the body, which is a differentiating factor from combination antibiotics used for complex, multi-drug applications.

General Purpose: Eliminating the Infectious Agent

The general purpose of Urofos is to effectively halt bacterial proliferation and progression of systemic infections by exerting a powerful bactericidal action—it actively kills susceptible bacteria. This definitive effect is achieved by targeting essential bacterial enzymes. Norfloxacin inhibits DNA gyrase and topoisomerase IV, two enzymes crucial for the management and replication of the bacterial cell’s genetic material. This mechanism of action supports the compound's role in the definitive elimination of the infectious agent. A typical scenario involves using Urofos to clear a persistent infection that requires systemic, broad-spectrum antibacterial coverage.

What side effects are possible with Urofos?

Possible Side Effects and Safety Information

The safety profile of Urofos (containing fosfomycin) is characterized by a range of documented adverse reactions, which include generally common, self-limiting events and less frequent but serious complications, as outlined in regulatory documents.

Documented Adverse Reactions

System Organ Class	Common Adverse Reactions (Examples)	Serious/Clinically Significant Reactions
Gastrointestinal	Diarrhea, nausea, indigestion (dyspepsia), abdominal pain	Antibiotic-associated colitis, which can be severe
Immune System	Rash, itching, hives (urticaria), asthma	Anaphylactic shock (life-threatening allergic reaction), angioedema (swelling of the face, throat)
Nervous System	Headache, dizziness, altered taste sensation (dysgeusia), tingling (paraesthesias)	Dizziness may affect the ability to drive or operate machinery
Infections	Vulvovaginitis	---

Safety Restrictions and Population-Specific Considerations

Serious Reactions: Immediate medical attention is required for any signs of a severe hypersensitivity reaction (e.g., anaphylaxis, angioedema) or severe, persistent diarrhea, as this may indicate antibiotic-associated colitis.

Pediatric Use: Safety and effectiveness in children under 12 years of age have not been established according to certain regulatory evaluations, and some agencies have recommended against the use of oral fosfomycin in this population.

Pregnancy and Lactation: The active substance crosses the placenta and is excreted in breast milk. Use during pregnancy and breastfeeding is generally limited to situations where it is clearly necessary, due to the potential for fetal or infant exposure.

General Precautions: Caution is advised for patients with a history of Clostridium difficile-associated diarrhea. Due to the potential for dizziness, patients should exercise caution when performing tasks requiring full alertness.

Overdose and Emergency Response

Urofos Overdose and When to Seek Help

Overdosage with Norfloxacin is officially documented to present with several severe manifestations across multiple physiological systems. These documented outcomes include neurological disturbances such as convulsive seizures, hallucinations, and confusion, alongside serious cardiovascular effects like QTc interval prolongation and the potential for Torsades de pointes, a life-threatening heart rhythm disorder. Acute overexposure also carries the risk of severe renal impairment, including kidney failure, and the potential for crystalluria at high doses.

Immediate action is mandatory if overexposure is suspected or if specific symptoms occur. Regulatory guidelines state that treatment must be discontinued immediately at the first sign of specific adverse events, such as tendon pain, inflammation, or any symptoms of peripheral neuropathy. Patients must seek immediate medical attention or contact emergency medical help right away if they experience signs of tendon rupture, severe allergic reactions, or breathing difficulty due to muscle weakness.

The official regulatory profile indicates that no specific antidote for Norfloxacin overexposure is currently documented. Management is therefore defined as symptomatic and supportive treatment. Due to cardiac risks, monitoring, including Electrocardiography (ECG), is advised. Special consideration is given to older patients and those with existing renal impairment, as they face an increased risk of severe outcomes.

Therapeutic Uses of Urofos

Main Uses and Benefits of Urofos

Urofos is a broad-spectrum antibiotic primarily utilized for the treatment of uncomplicated urinary tract infections (UTIs). Its active component belongs to the phosphonic acid derivative class, which works by inhibiting the early stages of bacterial cell wall synthesis.

Primary Indications

The medication is most commonly prescribed for the following conditions:

Acute Cystitis: It is indicated for the treatment of acute, uncomplicated bladder infections in women caused by susceptible strains of bacteria, such as Escherichia coli and Enterococcus faecalis.
Asymptomatic Bacteriuria: In certain clinical scenarios, such as during pregnancy, it may be used to treat significant bacterial presence in the urine even when symptoms are not present, to prevent complications like kidney infections.
Prophylaxis: It is sometimes used as a preventive measure prior to transurethral surgical procedures or diagnostic interventions to reduce the risk of post-operative urinary tract infections.

Therapeutic Benefits

Urofos offers several clinical advantages in the management of urinary infections:

Targeted Concentration: After administration, the medication achieves high concentrations in the urine, allowing it to act directly at the site of infection for a sustained period.
Broad Antimicrobial Activity: It is effective against a wide range of Gram-positive and Gram-negative pathogens, including many strains that have developed resistance to other common antibiotics.
Symptom Resolution: By eradicating the underlying bacterial infection, the medication helps alleviate the pain, urgency, and frequent urination associated with cystitis.

Eligibility and Restrictions for Use

Urofos, a fluoroquinolone antibiotic, is subject to strict regulatory rules that define eligibility based on patient demographics and medical history.

Who Must Not Use Urofos (Contraindicated)

The medication is absolutely contraindicated for specific groups, as stated in official labeling. This includes individuals with a known hypersensitivity to norfloxacin or any other quinolone class drug, and those with a prior history of tendinitis or tendon rupture related to fluoroquinolone use. Patients with a known history of Myasthenia Gravis are also prohibited from using the medicine. Furthermore, Urofos is contraindicated for all children and growing adolescents (typically under 18) and for women who are pregnant or breastfeeding.

Populations Requiring Conditional Use

Use of Urofos requires special caution and is restricted in several populations. This includes geriatric patients and individuals with impaired renal function (severe kidney problems). Caution is also mandated for patients with CNS disorders, those with a history of tendon issues, organ transplant recipients, and those with known risk factors for QT interval prolongation. Concomitant use with corticosteroid drugs also requires special caution, as this combination increases the risk of tendon damage.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define specific interaction patterns for Norfloxacin (Urofos) with other medicines and products. These interactions are classified primarily by their effect on drug concentration or their combined action in the body.

Absorption Interference and Timing Rules

The most common pharmacokinetic interaction involves absorption interference. Products containing polyvalent cations such as Antacids, Sucralfate, Iron, or Zinc supplements must be administered at least two hours apart from Norfloxacin. Similarly, ingesting Norfloxacin with meals, milk, or dairy products reduces its systemic absorption, necessitating administration at least one hour before or two hours after these items to ensure effectiveness.

Metabolic and Pharmacodynamic Interactions

Norfloxacin is an established inhibitor of the CYP1A2 enzyme. This interaction may lead to increased plasma concentrations of co-administered drugs metabolized by CYP1A2, including Theophylline and Caffeine, requiring monitoring for the substrate drug. Pharmacodynamic interactions include the potential to enhance the effect of oral anticoagulants like Warfarin, necessitating close monitoring of coagulation tests. Additionally, co-administration with other QT-prolonging drugs may increase the risk of QTc interval prolongation, an effect noted as more significant in the elderly population. The combination of Norfloxacin with Nitrofurantoin is not recommended due to potential antagonism of antibacterial activity.

Mechanism of Action

How Urofos Works

Urofos (Norfloxacin) exerts its action exclusively within the bacterial cell through a bactericidal mechanism. The drug functions as an enzyme inhibitor, primarily targeting two essential bacterial enzymes: DNA Gyrase (Topoisomerase II) and Topoisomerase IV.

Norfloxacin binds to and stabilizes the transient DNA-enzyme cleavage complex that forms during DNA manipulation. This stabilization prevents the necessary re-ligation of the severed DNA strands, immediately halting the enzyme's function.

This molecular action triggers a lethal cascade resulting in the rapid accumulation of extensive double-stranded DNA breaks within the bacterial chromosome. The resulting genomic damage overwhelms the cell's repair mechanisms, causing the cessation of essential bacterial functions and inducing active cell death. The physiological consequence of this targeted action is the active killing of susceptible microbial cells.

Mechanistic activity is constrained by bacterial counter-mechanisms, specifically target modification (mutations in the target enzymes reducing binding affinity) and the activity of efflux pumps that actively expel the drug from the bacterial cell, preventing it from reaching inhibitory concentration.

Dosage and Administration Information

How to Use Urofos: Official Administration Guidelines

Urofos, which contains the active ingredient norfloxacin, is used according to established administration instructions. These guidelines define the proper dose, frequency, and conditions for its administration.

Approved Route and Dosing

The medication is available as a 400 mg film-coated tablet intended for oral administration. The tablet must be swallowed whole with water; it should not be crushed, chewed, or divided.

Dosing is typically 400 mg twice daily (every 12 hours) for most urinary tract infections (UTIs) and prostatitis. The treatment duration varies by condition:

Indication	Standard Dose	Frequency	Typical Duration
Uncomplicated Acute Cystitis	400 mg	Twice daily	3 days
Complicated UTIs	400 mg	Twice daily	10 to 21 days
Uncomplicated Gonorrhea	800 mg	Single dose	1 day

Administration Timing and Adjustments

To ensure proper absorption, Urofos tablets must be taken on an empty stomach: at least one hour before or two hours after a meal or the ingestion of dairy products. Furthermore, the drug should be taken at least two hours before or after any products containing minerals, such as antacids, sucralfate, or iron/zinc supplements.

Specific adjustments are required for patients with reduced kidney function. For individuals with a Creatinine Clearance leq 30 mL/min/1.73 m^2, the standard frequency is typically reduced to 400 mg once daily. Completing the full course of treatment, even if symptoms improve, is necessary for proper use.

Recent Clinical Evidence

Research evidence / Overview of Studies for Urofos

Evidence for Use in Uncomplicated Cystitis

Research examining the use of Urofos for conditions associated with acute or disruptive episodes, such as simple bladder infections (uncomplicated acute cystitis), primarily involves short-term Randomized Controlled Trials (RCTs) and comparative trials (studies comparing microbiological and clinical outcomes against other treatments or controls). These studies were generally applied in research contexts involving adult women who had been diagnosed with this common type of lower urinary tract infection. The studies monitored two main types of outcomes: Bacteriological Eradication, which assessed whether the infection-causing bacteria were cleared from the urine sample, and Clinical Cure, used in research exploring how outcomes related to physical discomfort, such as pain or urgency, changed over a short period.

Evidence for Preventive Use (Prophylaxis)

Urofos was also evaluated in research exploring study outcomes related to the prevention of infections, which is known as prophylaxis. Studies examined its use for conditions where research explores the reduction of urinary tract infection incidence, especially those that may arise after certain procedures, such as trans-urethral maneuvers. This research monitored outcomes related to infection incidence. Studies described patterns related to the measurement of infection rates in the immediate short-term when the agent was monitored.

Long-Term Studies and Follow-Up Data

The body of evidence informing the initial regulatory authorization for Urofos comes from trials where follow-up periods were generally short. For the treatment of acute cystitis, studies primarily monitored patient experiences and microbiological outcomes over defined time intervals that lasted from the start of the study period up to approximately six weeks. This research provides insight into short-term changes but does not fully establish the long-term status regarding infection recurrence over many months.

What Is Still Uncertain About Urofos Research

The broader evidence landscape contributes to understanding symptom patterns, but several areas of uncertainty remain. One major limitation in the evidence is the rising pattern of antibiotic resistance, which means the findings from older studies, where resistance was less prevalent, may not fully reflect the agent's performance in current settings. Research has primarily focused on conditions associated with acute or disruptive episodes in the lower urinary tract, and there is limited evidence available regarding research in more complex or broader systemic infections. This means research describes group patterns but does not determine whether an individual will respond similarly across all types of infections or over long periods.

Frequently Asked Questions (FAQ)

Common questions about Urofos (FAQ)

Q: Does Urofos work immediately after taking it?

According to research data examining uncomplicated infections, the median time until patients experienced the disappearance of symptoms was 3 days after treatment began. This indicates that while the medicine starts working immediately on the bacteria, the noticeable relief may take a few days.

Q: How long does it take for Urofos to clear the infection?

Clinical studies monitor the drug's effect by checking for bacterial eradication (the clearing of infection-causing bacteria). Data shows that in some cases, eradication can be achieved as early as the third day of treatment. Short-term efficacy, which monitored the clearance of bacteria, was measured up to 13 days post-treatment.

Q: What foods or drinks should I avoid when taking Urofos?

Official caution advises avoiding or limiting alcohol consumption while taking this medicine. This is because drinking alcohol may increase the risk of dizziness or lightheadedness, which is a documented side effect of Urofos. The official guidance already provides strict timing rules for food, milk, and certain mineral products, which should be followed carefully.

Q: Are there any long-term side effects associated with Urofos?

Regulatory warnings indicate that certain serious side effects, such as tendon rupture, can occur during treatment or up to several months after the medicine is finished. In rare instances, these effects may be permanent or long-lasting.

Q: Is Urofos a strong antibiotic?

Urofos is classified in official documents as a synthetic, broad-spectrum antibacterial agent. This means it is active against a wide range of gram-positive and gram-negative bacteria.

Q: Can older adults use Urofos safely?

Use in older adults requires special caution. According to the official product information, the drug may be eliminated more slowly from the body in this population. Additionally, the risk of certain serious side effects, such as serious heart rhythm changes, may be increased in the elderly population.

Q: What is the shelf life of Urofos powder?

Official guidelines recommend storing the Urofos tablet at controlled room temperature, generally below 30 C or around 25 C. Official storage guidelines require the medicine to be protected from excessive heat, light, and moisture to maintain its quality.

Q: Does Urofos help with kidney infections, or just bladder infections?

Urofos is approved for some urinary tract infections, but specific regulatory bodies have recommended withdrawing authorization for its oral use in treating complicated kidney infections (pyelonephritis). This action was based on the conclusion by regulatory agencies that the potential benefits no longer outweigh the risks for this specific use.

Q: Is Urofos effective against all types of bacteria that cause UTIs?

The medication is only used to treat infections that are caused by susceptible bacteria that respond to the drug. It is important to note that Urofos is not effective against non-bacterial infections, such as those caused by viruses (e.g., the common cold or flu).

Q: What does official data say about the success rate of Urofos?

Studies measured short-term efficacy based on the rate of bacterial elimination in patients with uncomplicated infections. Official clinical data reported this measure to be in the range of 93.8% to 96.6% in different treatment groups studied.

Q: What types of research have been done on Urofos for children?

According to official regulatory guidance, the safety and effectiveness of the oral tablet have generally not been established in children and adolescents under 18 years of age. The oral form has limitations regarding pediatric research.

Q: Is Urofos safe to take if I have liver problems?

Official guidance notes that a dose adjustment may be needed for patients who have known liver impairment or disease. Official guidance requires that any use in this population be determined and monitored by a healthcare professional.

Q: What happens if I miss a dose of Urofos?

Patient information generally includes an instruction to skip the missed dose if it is almost time for the next scheduled dose, and instead take the next dose as intended. A common warning is to avoid taking two doses at once. Specific guidance should always be confirmed with a healthcare professional.

Q: Can Urofos be used by men?

The official drug indications include conditions such as prostatitis and gonorrhea, which are diseases relevant to the male population. Contraindications for the medicine primarily focus on women (pregnancy/lactation), growing adolescents, and patients with specific pre-existing medical conditions.

Q: Is Urofos considered a last-resort antibiotic?

Official prescribing considerations state that fluoroquinolones, including Urofos, should be reserved for use when alternative agents are ineffective or contraindicated for the patient. The regulatory guidance requires the medicine to be reserved for situations where alternative agents are deemed ineffective or contraindicated.

Q: Are there any reported interactions between Urofos and pain relievers like ibuprofen?

Official warnings state that taking Urofos with a pain reliever classified as an NSAID (Non-Steroidal Anti-Inflammatory Drug), such as ibuprofen, may increase the risk of central nervous system side effects and seizures.

Q: Can I use Urofos if I have a history of kidney stones?

Cautionary warnings note the potential for crystalluria (the formation of crystals in the urine) to occur, particularly if the dose is too high. Official information recommends patients drink sufficient fluids to ensure adequate hydration while taking the medication.

Q: Do I need to take Urofos with a full glass of water?

The medication guide generally advises taking the tablet with a glass of water. Furthermore, official guidance states that patients should drink plenty of fluids while on the medication to promote adequate hydration.

Q: Is Urofos safe for people who are lactose intolerant?

Based on the official list of inactive ingredients provided in the FDA description, the Urofos formulation does not typically include lactose.

Q: Does Urofos affect the results of any lab tests?

Regulatory documents indicate that the drug may cause changes in the results of certain lab tests. This can include liver function tests and the prothrombin time, which is a measurement of blood clotting ability.

Q: Are there any specific safety alerts for Urofos in certain countries?

Specific regulatory bodies, such as those in the Republic of Ireland, have issued restrictions for the drug's use. These decisions were based on concerns about the risk of certain infections and permanent nerve and tendon injuries.

Q: Does Urofos have potential interactions with common herbal supplements?

Official guidance consistently advises patients to inform their healthcare provider about all medicines, including herbal products and supplements. This is important because any potential interactions should be assessed before the combination is used.

Q: How long is the drug detectable in the system?

According to clinical pharmacology data, the effective half-life (the time required for the amount of drug in the body to be reduced by half) is reported to be 3 to 4 hours.

How should Urofos be stored and disposed of?

How to Store and Dispose of Urofos (Norfloxacin)

Official regulatory guidelines define specific conditions for storing Urofos tablets to maintain their quality.

Storage Requirements

Urofos must be stored at controlled room temperature, generally defined as below 30 C, and should be kept from freezing. The medication requires protection from light, moisture, and excessive heat. Tablets must be stored in their original package or a tightly closed container.

Disposal and Safety

For child safety, the medicine must be stored out of the reach of children. Unused, unwanted, or expired Urofos must not be disposed of in household trash or wastewater systems. Patients are instructed to return the product to a pharmacist or healthcare professional for proper disposal, often through an official take-back program.

Urofos